Tourmaline Bio, Inc. (TRML)
NASDAQ: TRML · Real-Time Price · USD
16.65
-0.08 (-0.48%)
At close: Mar 28, 2025, 4:00 PM
16.62
-0.03 (-0.19%)
After-hours: Mar 28, 2025, 7:57 PM EDT
Tourmaline Bio Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Tourmaline Bio stock have an average target of 45.2, with a low estimate of 25 and a high estimate of 58. The average target predicts an increase of 171.47% from the current stock price of 16.65.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Tourmaline Bio stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 3 | 4 | 4 | 4 | 2 |
| Buy | 1 | 0 | 2 | 2 | 3 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 3 | 6 | 6 | 7 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wedbush | Wedbush | Buy Maintains $42 → $43 | Buy | Maintains | $42 → $43 | +158.26% | Mar 14, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $49 → $50 | Strong Buy | Maintains | $49 → $50 | +200.30% | Mar 14, 2025 |
| Wedbush | Wedbush | Buy Initiates $42 | Buy | Initiates | $42 | +152.25% | Mar 6, 2025 |
| LifeSci Capital | LifeSci Capital | Buy Initiates $58 | Buy | Initiates | $58 | +248.35% | Feb 24, 2025 |
| Guggenheim | Guggenheim | Strong Buy Reiterates n/a | Strong Buy | Reiterates | n/a | n/a | Dec 11, 2024 |
Financial Forecast
Revenue This Year
123.33M
from 26.58M
Increased by 363.93%
Revenue Next Year
n/a
from 123.33M
EPS This Year
-3.53
from -2.89
EPS Next Year
-4.36
from -3.53
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 63.0M | 63.0M | 63.0M | ||
| Avg | 7.7M | 8.7M | 20.8M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 137.0% | 723.5% | 620.6% | ||
| Avg | -71.2% | 14.3% | 138.0% | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.89 | -2.98 | -3.14 | ||
| Avg | -3.53 | -4.36 | -5.49 | ||
| Low | -4.56 | -5.85 | -9.44 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.